Key result
GLADEL 2.0 biomarker study enrolls ~800 SLE patients across multiple centers.
Cohort (n=1,438)
Yes
Answers are grounded in this paper and cite their sources.
Introduction: After more than 20 years of sustained work, the Latin American Group for the Study of Lupus (GLADEL) has made a significant number of contributions to the field of lupus, not only in the differential role that race/ethnicity plays in its course and outcome but also in several other studies including the beneficial effects of using antimalarials in lupus patients and the development of consensus guidelines for the treatment of lupus in our region. Methods: A new generation of “Lupus Investigators” in more than 40 centers throughout Latin America has been constituted in order to continue the legacy of the investigators of the original cohort and to launch a novel study of serum and urinary biomarkers in patients with systemic lupus erythematosus. Results: So far, we have recruited 807 patients and 631 controls from 42 Latin-American centers including 339 patients with SLE without renal involvement, 202 patients with SLE with prevalent but inactive renal disease, 176 patients with prevalent and active renal disease and 90 patients with incident lupus nephritis. Conclusions: The different methodological aspects of the GLADEL 2.0 cohort are discussed in this manuscript, including the challenges and difficulties of conducting such an ambitious project.
No takes yet. Share an insight, caveat, or question.
Gómez‐Puerta et al. (2021) conducted a cohort in Systemic lupus erythematosus (SLE) and lupus nephritis (n=1,438). Serum and urinary biomarkers in SLE vs. Controls (n=631) and SLE patients without renal involvement (n=339) was evaluated. The GLADEL 2.0 biomarker study has recruited 807 SLE patients (including 90 with incident lupus nephritis and 176 with active renal disease) and 631 controls across 42 centers.
Synapse has enriched 10 related papers. Consider them for comparative context: